Positron Stock Price, News & Analysis

Positron (OTC: POSC) has announced the sale of four PET-CT scanners to a prominent cardiovascular diagnostics provider. The company's molecular imaging systems feature a 72 cm gantry and high-sensitivity acquisition technology, reducing radiation exposure while maintaining compact design.

The PET-CT systems are engineered for both cardiology and oncology applications, offering advanced data acquisition capabilities for faster and more precise scans. Key features include the smallest footprint in their class, versatility for cardiac and tumor imaging, and brain studies capabilities.

According to Adel Abdullah, President of Positron, this sale reflects growing demand for cardiac PET imaging. The company aims to make PET technology more accessible through cost-effective solutions and comprehensive support services.

Positron (POSC) has secured an $8 million equity investment through the sale of 8 million common shares to two strategic investors. The capital will fund the company's expansion in the PET-CT imaging market, particularly in nuclear cardiology and oncology.

The funding will support multiple strategic initiatives, including:

• Enhanced sales and marketing efforts
• Expansion of sales personnel
• Product development and offerings
• Strengthening industry partnerships
• Market expansion in North America and Europe

The company plans to use this capital to resume SEC filings and pursue an uplisting to a senior stock exchange. According to President Adel Abdullah, this investment positions Positron to capitalize on increasing PET-CT imaging adoption and develop a competitive edge in the marketplace.

Positron (OTC: POSC) has secured an agreement for three NeuSight PET-CT 64-slice scanners under its Prime Rental Program with a leading cardiovascular practice. The NeuSight PET-CT features a 72 cm gantry and high-sensitivity acquisition technology, offering reduced radiation exposure and superior imaging capabilities.

The system boasts the smallest footprint among PET-CT systems and excels in both cardiology and oncology studies. Key features include advanced data acquisition technology for faster and more precise scans, supporting various molecular imaging applications including heart, tumor, and brain studies.

Positron (OTC: POSC) has announced the sale of its Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist. The Attrius, a 2D quantitative dedicated PET scanner, provides high-resolution images and blood flow data for coronary flow reserve analysis. The NeuSight PET-CT features a spacious 72 cm gantry and high-sensitivity acquisition technology, reducing radiation exposure while maintaining superior imaging capabilities.

The NeuSight PET-CT system, notable for its smallest footprint and lightest weight in its class, supports both cardiology and oncology applications. It enables faster, more precise scans for heart, tumor, and brain studies. The company's president, Adel Abdullah, highlighted these sales as indicators of growing market momentum and emphasized their technology's role in advancing PET imaging and cardiovascular care.

Positron (OTC: POSC) has announced a significant business agreement for its NeuSight PET-CT scanners, securing deals for four sales and four rentals of their 64-slice systems to a prominent cardiovascular diagnostics provider. The NeuSight PET-CT scanner features a spacious 72 cm gantry and high-sensitivity acquisition technology, reducing radiation exposure while maintaining superior imaging quality.

The system stands out for having the smallest footprint and lightest weight in its category, while offering advanced capabilities for both cardiology and oncology applications. The technology enables faster and more precise scans, supporting various molecular imaging applications including heart, tumor, and brain studies. The company's offering includes comprehensive clinical support and training through their network of industry-leading physicians.

Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL), has appointed Joseph Oliverio as President and CEO. Oliverio brings over three decades of leadership experience in nuclear medicine, medical devices, and radiopharmaceuticals, including positions at Ionetix, IMAGIN Molecular , and Positron (OTC: POSC).

The appointment comes as Actineer scales its Actinium-225 (Ac-225) manufacturing capabilities to supply the radiopharmaceutical industry. Oliverio's previous roles include VP of Clinical Operations at Ionetix, where he led cardiac radiopharmaceutical strategy and managed clinical trials, and President/CEO of IMAGIN Molecular At Positron , he managed a Neusoft joint venture, expanded PET scanner business, and led multiple funding rounds.

Oliverio holds an MBA in Technology Management and a BS in Nuclear Medicine Technology. The appointment aims to strengthen Actineer's position as a major global supplier of Ac-225, supporting the development of targeted alpha radiopharmaceuticals for cancer treatment.

Positron (OTC: POSC), a molecular imaging medical device company specializing in PET and PET-CT imaging systems, has announced its engagement with Skyline Corporate Communications Group to manage investor relations and corporate communications initiatives. Based in Boston and New York City, Skyline will help Positron effectively communicate its business strategies and market positioning to investors.

The engagement comes as Positron advances its PET-CT initiatives and moves toward commercialization in the nuclear imaging device industry. The company aims to become an SEC-reporting entity and pursue listing on a senior stock exchange. This partnership is expected to enhance Positron's market visibility and shareholder engagement while showcasing its innovative solutions and strategic milestones to the investment community.

Positron (OTC: POSC) has partnered with Upbeat Cardiology Solutions to expand its PET-CT imaging systems and services. The collaboration focuses on providing cardiology practices with NeuSight PET-CT 64 Slice scanner technology and turnkey solutions. Upbeat Cardiology Solutions will offer comprehensive services including equipment acquisition, installation, staff training, and isotope supply. The partnership aims to make cardiac PET-CT imaging more accessible to private practices, offering superior diagnostic accuracy, reduced scan times, and higher reimbursement rates compared to traditional SPECT imaging.

Positron (OTC: POSC) has launched its Prime Rental Program, offering PET-CT systems with comprehensive services for a single monthly fee. This program aims to make advanced imaging technology accessible to practices of all sizes by eliminating upfront capital expenditure. The package includes:

• Positron's PET-CT 64 Slice scanner
• Clinical & technical support
• Technician training services
• Preventative maintenance

Key benefits include flexible financing, comprehensive services, future upgrades, and potential tax advantages. The NeuSight PET-CT, designed for both cardiology and oncology applications, features a 72cm gantry, high-sensitivity acquisition technology, and the smallest footprint in its class. This initiative aims to stimulate demand for PET-CT technology and accelerate its adoption in healthcare practices.